Microsoft PowerPoint - Roche IR Event EULAR Final.ppt

More documents

Recommendations

Info

<strong>Roche</strong>’s key therapeutic areas Current and future pillars of growth Oncology Xeloda MabThera Herceptin Avastin Tarceva C.E.R.A. Pertuzumab ARQ 12 phase I compounds ON HAND Autoimmune MabThera Actemra CellCept Ocrelizumab Pamapimod (p38 kin inh) 4 phase I compounds PROMISING LATE STAGE Metabolic R1440 GKA R1583 GLP-1 R1658 CETP Inh R1439 dual PPAR 2 phase I compounds Virology Tamiflu Pegasys R1626 Polymerase Inhib. R7227 Protease Inhibitor R7128 Polymerase Inhib. R7025 next gen. IFN EMERGING MID-TERM Neurology/ Psychiatry 6 phase I compounds EARLY STAGE 6
RA market continues to grow Biologic therapies are the significant driver 20'000 Sales of RA treatments 15.6 bn In millions CHF 15'000 10'000 8.6 bn Biologic agents Conventional DMARDs, steroids & pain killers 5'000 0 2005 2010 Sources: Decision Resources, Evaluate Pharma, IMS, Wood Mackenzie 7
Page 2 and 3: Roche Analyst Meeting EULAR 2007 Ba
Page 4 and 5: Introduction Dr. Karl Mahler Head o
Page 8 and 9: RA: A very concentrated market 6.00
Page 10 and 11: Increased penetration of biologics
Page 12 and 13: Actemra: The OPTION trial results P
Page 14 and 15: Elevated IL-6 plays central role in
Page 16 and 17: The OPTION study TOcilizumab Pivota
Page 18 and 19: Demographics Intent-to-treat popula
Page 20 and 21: Results: Efficacy and safety 20
Page 22 and 23: Rapid onset of action with tocilizu
Page 24 and 25: Tocilizumab induces rapid CRP norma
Page 26 and 27: Most frequently reported AEs Incide
Page 28 and 29: Adverse events Consistent with thos
Page 30 and 31: MabThera: Longer-term repeat treatm
Page 32 and 33: Rituximab selectively targets CD20-
Page 34 and 35: Rituximab: Advancing in RA Initial
Page 36 and 37: Inhibition of radiographic progress
Page 38 and 39: Efficacy: Repeat treatment courses
Page 40 and 41: Patient exposure to repeat courses
Page 42 and 43: ACR scores are sustained Repeated c
Page 44 and 45: Consistent time intervals between t
Page 46 and 47: More than 2400 patient-years As of
Page 48 and 49: No increase in infection rates with
Page 50 and 51: IgM RF levels by treatment course o
Page 52 and 53: Rates of serious infection Similar
Page 54 and 55: Roche’s franchise in autoimmune d
Page 56 and 57:
Overview of autoimmune disorders IN
Page 58 and 59:
Not all patients respond to current
Page 60 and 61:
Major players are active in this ar
Page 62 and 63:
Actemra Potential to become a signi
Page 64 and 65:
Ocrelizumab in autoimmune diseases
Page 66 and 67:
Multiple sclerosis An emerging ther
Page 68 and 69:
Prevalence of MS in Europe ~260,000
Page 70 and 71:
Development hurdles & treatment cha
Page 72 and 73:
Roche in autoimmune disorders Roche
show all

Microsoft PowerPoint - Roche IR Event EULAR Final.ppt

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?